Question explored with the scientific record
Conversation so far
- 1 Why is Ajovy available only in 225mg syringes? Why is there no 175mg, for example? How did the drug manufacturer arrive at that dose and can I see that data? What dose ranges did they test?
- 2 What does it imply if an adult can take Ajovy 225mg every two months instead of monthly? does it imply the 225mg dose is an overshoot for this particular person? if the half-life is 30 days and the drug works great for 60 days, what do we learn from that?
- 3 Do any guidelines address stretching Ajovy dosing beyond 30 days?
- 4 Are there any studies on dosing at 45 or 60 days for Ajovy?
- 5 what are the long-term impacts of mAbs?
- 6 what about mAbs in general, not these ones specifically. what do we know about their long-term safety profile?
Answered on this page ↓
what about mAbs in general, not these ones specifically. what do we know about their long-term safety profile?
The short version: the retrieved evidence does not answer the question about long-term safety of monoclonal antibodies in general, because the studies cover different drugs, different diseases, and short time frames.
The evidence block contains studies on specific mAbs for asthma [1], migraine [3], RSV prevention [5, 7], and cancer [2, 4], plus a preclinical antibody-drug conjugate [4] and a 2008 review of CLL therapies [2]. None of these track patients beyond a few months to two years. The longest follow-up is the fremanezumab migraine study at 12 weeks [3]. The RSV antibody nirsevimab is given as a single dose to infants, with efficacy data through one season but no long-term safety follow-up [5, 7].
What the evidence does show is that different mAbs have different safety profiles tied to their targets. The anti-CGRP antibody fremanezumab had mostly injection-site reactions and low rates of anti-drug antibodies (about 0.4 in 100 people) over 12 weeks [3]. The anti-MASP-2 antibody SHR-2010 showed no organ toxicity in monkeys dosed for 26 weeks [6]. But these are short windows for drugs that patients may take for years.
The fundamental problem is that mAbs are not a single class. They target different molecules, have different half-lives, and are given for different durations. A general statement about "mAb long-term safety" is not supported by the evidence here. Each drug needs its own long-term data, and for most mAbs, that data does not exist in these records.
My call: the evidence does not establish long-term safety for mAbs as a class, because the studies are short, drug-specific, and disease-specific. Confidence: low for any general claim.
Sources used 7
-
Adverse Events of Biologics in Severe Asthma
This narrative review summarizes published evidence indicating that monoclonal biologic therapies for severe asthma have low rates of local reactions and anaphylaxis, with no clear signal for increased malignancy, stroke, or mortality.
DOI: 10.1007/s40521-026-00411-9 -
New Therapies for Patients with Chronic Lymphocytic Leukemia
A comprehensive 2008 review of emerging therapies for chronic lymphocytic leukemia (CLL), detailing monoclonal antibodies (ofatumumab, GA-101, IMMU-106, epratuzumab, lumiliximab, galiximab, HCD122/SGN-40), bendamustine, antisense oligonucleotides (oblimersen), flavopiridol, bryo…
DOI: 10.2174/157339408786413380 -
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials
Pooled safety analysis of four randomized trials found fremanezumab generally safe and well tolerated in adults with chronic or episodic migraine.
DOI: 10.1111/head.13534 -
Supramolecular Site-Specific Antibody Drug Conjugates Outperform Cysteine-Conjugated Analogs in Pancreatic Peritoneal Carcinomatosis
A site-specific supramolecular ADC, α-DEspRSMA-MMAE2, targeting DEspR with two MMAE molecules per antibody improved survival and reduced tumor burden in a rat orthotopic pancreatic peritoneal carcinomatosis model compared with cysteine-conjugated ADC and native antibody.
DOI: 10.64898/2026.08.05.743073 -
RSV-Prophylaxe
Long-acting monoclonal antibody Nirsevimab and maternal vaccine Abrysvo are transforming RSV prophylaxis by enabling less frequent dosing and broader protection, with trial data showing substantial reductions in RSV-LRTI and hospitalization in infants.
DOI: 10.1007/s00608-023-01171-4 -
Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases
A fully humanized anti-MASP-2 monoclonal antibody (SHR-2010) was developed and thoroughly preclinically characterized, showing potent, selective inhibition of the lectin pathway in human and rhesus serum, a long half-life with excellent subcutaneous bioavailability in non-human …
DOI: 10.2147/jir.s522657 -
Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review
Nirsevimab is a single-dose long-acting monoclonal antibody preventing RSV lower respiratory tract disease in infants, with high efficacy and effectiveness across trials and real-world programs, favorable safety, complementary use with maternal vaccination, and surveillance for …
DOI: 10.1080/21645515.2026.2726689